8-K: Village Farms Achieves Record Profitability in Q2 2025

Village Farms International reported record profitability and performance from continuing operations in Q2 2025, driven by strong cannabis segment growth and strategic asset privatization.

Summary

• Consolidated net income from continuing operations reached $9.9 million, or $0.09 per share, a significant improvement from a $16.6 million net loss in Q2 2024.
• Total consolidated net income, including discontinued operations, was $26.5 million, or $0.24 per share, compared to a $23.5 million net loss in the prior year.
• Adjusted EBITDA from continuing operations hit a record $17.1 million, up from $2.9 million in Q2 2024, with an adjusted EBITDA margin of 28.6%.
• Year-to-date consolidated operating cash flow from continuing operations was $22.3 million, a substantial turnaround from a ($3.7 million) outflow.
• The company ended Q2 2025 with a strong cash position of $65 million.
• The Canadian Cannabis segment saw net sales increase 9% to $44.5 million (C$61.4 million) and adjusted EBITDA surge 146% to $11.9 million (C$16.5 million).
• International medical export sales for Canadian Cannabis increased 690% year-over-year.
• The Netherlands Cannabis (Leli Holland) commenced sales in Q1 2025, reporting $2.5 million in net sales, $0.8 million in net income, and $1.2 million in adjusted EBITDA.
• The produce segment's continuing operations improved to a net income of $4.3 million from a $1.3 million loss, partly due to a vendor settlement related to the Tomato Brown Rugose Fruit Virus (ToBRFV) infestation.
• The company completed the privatization of certain produce assets on May 30, 2025, receiving $40 million in cash and a 37.9% equity interest in Vanguard Food LP, reclassifying these operations as discontinued.

Sentiment

Score: 9

Explanation: The filing reports record profitability, significant improvements across key financial metrics, strong cash generation, and successful strategic initiatives like the produce asset privatization and cannabis capacity expansion. The outlook is positive with sustainable trends and growth plans. While some sales channels saw decreases, these were attributed to a strategic shift towards higher-margin products, indicating a focus on profitability over volume. The overall tone and results are overwhelmingly positive.

Positives

• Record profitability and performance from continuing operations in Q2 2025.
• Consolidated net income from continuing operations of $9.9 million ($0.09/share) compared to a net loss of $16.6 million (($0.15)/share) in Q2 2024.
• Consolidated net income of $26.5 million ($0.24/share) compared to a net loss of $23.5 million (($0.21)/share) in Q2 2024.
• Record Adjusted EBITDA from continuing operations of $17.1 million, up from $2.9 million in Q2 2024.
• Adjusted EBITDA margin from continuing operations significantly increased to 28.6% from 5.4%.
• Year-to-date consolidated operating cash flow from continuing operations was $22.3 million, a strong positive shift from ($3.7 million).
• Strong cash position of $65 million at the end of Q2 2025.
• Canadian Cannabis net sales increased 9% to $44.5 million (C$61.4 million).
• Canadian Cannabis international medical export sales increased 690% year-over-year.
• Canadian Cannabis gross margin increased to 39% from 26%.
• Canadian Cannabis net income increased 369% to $6.5 million (C$9.1 million).
• Canadian Cannabis Adjusted EBITDA increased 146% to $11.9 million (C$16.5 million).
• Canadian Cannabis cash flow from operations increased 233% to $18.0 million (C$24.6 million).
• U.S. Cannabis (Balanced Health Botanicals) net loss significantly improved to $0.2 million from $12.3 million.
• U.S. Cannabis Adjusted EBITDA turned positive at $45,000 from ($0.2 million).
• Netherlands Cannabis (Leli Holland) commenced sales with $2.5 million in net sales, $0.8 million net income, and $1.2 million Adjusted EBITDA.
• Continuing produce operations improved to a net income of $4.3 million from a $1.3 million loss, partly due to a vendor settlement.
• Successful privatization of certain produce assets, yielding $40 million cash and a 37.9% equity interest in Vanguard Food LP.
• Refinanced Canadian Cannabis Term Loans with a lower variable interest rate (below 6.0%, a 250 basis point improvement) and extended maturity to February 7, 2028.
• Maintained a top three overall market share position in Canada and the number one position in dried flower year-to-date through July.
• Achieved the high end of its targeted gross margin range (30-40%) for the second consecutive quarter in Canadian Cannabis.
• Board approved investment to expand cannabis cultivation capacity in Delta 2 greenhouse by 40 metric tons, funded by existing cash.
• International export sales achieved previous full-year target in the first six months of 2025.
• Leli Holland products are represented in 66 of 80 participating coffeeshops (82.5% market penetration).
• Construction of Leli Holland's Phase II facility in Groningen is on track for Q1 2026, expected to quintuple total annualized production capacity.
• Regained compliance with Nasdaq minimum closing bid price requirement.

Negatives

• Canadian Cannabis retail branded sales decreased 20% due to a planned mix shift toward higher-margin products.
• Canadian Cannabis non-branded (wholesale) sales decreased 15%.
• U.S. Cannabis (Balanced Health Botanicals) net sales decreased to $3.8 million from $4.3 million.

Risks

• Limited operating history in the cannabis and cannabinoids industry, including Pure Sunfarms, Rose LifeScience, and Balanced Health Botanicals.
• Limited operational history of the Delta RNG Project and Leli Holland B.V.
• Uncertainty regarding the legality and regulatory status of cannabis in the United States.
• Risks related to the integration of Balanced Health and Rose into the consolidated business.
• Risks relating to obtaining additional financing on acceptable terms, including dependence upon credit facilities and dilutive transactions.
• Potential difficulties in achieving and/or maintaining profitability.
• Variability of product pricing.
• Inherent risks in the cannabis, hemp, CBD, cannabinoids, and agricultural businesses.
• Market position and competitive position.
• Ability to leverage current business relationships for future business involving hemp and cannabinoids.
• Ability of Pure Sunfarms and Rose to cultivate and distribute cannabis in Canada as well as exports.
• Risks related to the start-up of international production at Netherlands operations under Leli.
• Existing and new governmental regulations, including risks related to regulatory compliance and obtaining and maintaining licenses.
• Legal and operational risks relating to expected conversion of greenhouses to cannabis production in Canada and in the United States.
• Risks related to rules and regulations at the U.S. Federal (Food and Drug Administration and United States Department of Agriculture), state and municipal levels with respect to produce and hemp, cannabidiol-based products commercialization.
• Retail consolidation, technological advances, and other forms of competition.
• Transportation disruptions.
• Product liability and other potential litigation.
• Retention of key executives.
• Labor issues.
• Uninsured and underinsured losses.
• Vulnerability to rising energy costs.
• Inflationary effects on costs of cultivation and transportation.
• Recessionary effects on demand of products.
• Environmental, health and safety risks.
• Foreign exchange exposure.
• Risks associated with cross-border trade and the potential for tariffs and other trade restrictions.
• Difficulties in managing growth.
• Restrictive covenants under credit facilities.
• Natural catastrophes.
• Elevated interest rates.
• Tax risks.

Future Outlook

The company believes the positive trends observed in Q2 2025 are sustainable and that capacity expansion projects in Canada and the Netherlands position it for continued profitable growth in 2026 and beyond. It expects similar international export sales performance in the second half of 2025 compared to the first half. The Phase II facility in Groningen is on track to be operational in Q1 2026 and is expected to quintuple total annualized production capacity. The company plans to launch hash products in the Netherlands during the fourth quarter. The application for a Texas medicinal marijuana license remains pending, and if awarded, the company plans to structure an acceptable ownership and comply with regulations to enter the U.S. THC market.

Management Comments

• "Our second quarter results demonstrate the improving earnings potential of Village Farms and our continued success in scaling a profitable global cannabis enterprise."
• "Second quarter performance reflected record levels of profitability since we expanded into cannabis in 2017, and eclipsed several records set during our nearly 20-year history as a publicly traded company."
• "Our teams are excelling during a period of rapid change for the organization, and energized by the many pockets of upside opportunity that we see across virtually every aspect of our business."
• "The recent closing of our produce transaction has coincided fortuitously with several other powerful catalysts, including our commencement of sales in Hollands adult-use market, success of our recent initiatives to align our product portfolio toward higher-margin SKUs, and a continuing wave of additional countries around the world following Canadas lead with pragmatic approaches to regulating cannabis."
• "We are proud to be part of an emerging, vibrant global cannabis ecosystem, proud to be leveraging our 36-years in controlled environment agriculture to become a partner of choice in the cannabis community, and proud to be in a leadership position that enables us to self-fund an additional 40 metric tons of annual cultivation capacity to serve our Canadian and international customers."
• "While we are benefiting from multiple catalysts unlocking value for our stakeholders, we continue to see meaningful potential for additional long-long-term value creation through our ownership interest in our newly formed produce entity and future optionality of our U.S. based greenhouse assets and operations."
• "We believe the trends observed in our business during the second quarter are sustainable, and that our capacity expansion projects in Canada and the Netherlands position us for continued profitable growth in 2026 and beyond."
• "We are growing organically, profitably and generating positive free cash flow, and we believe the strength of our balance sheet will enable us the flexibility to make additional growth investments that will drive strong returns for shareholders."

Industry Context

The company's strong Q2 2025 results, particularly in cannabis, align with the broader trend of increasing global cannabis legalization and market maturation, especially in medical and adult-use segments. The significant growth in international medical export sales and the successful commencement of sales in the Netherlands' adult-use market demonstrate the company's ability to capitalize on emerging global opportunities. The strategic shift away from certain produce assets, while maintaining a minority interest, allows for a sharper focus on the higher-growth cannabis sector, a move many diversified agricultural companies are considering or undertaking. The emphasis on higher-margin SKUs in Canadian cannabis reflects a market-wide trend towards profitability over pure volume, as competition intensifies.

Comparison to Industry Standards

• The Canadian Cannabis segment's gross margin of 39% and Adjusted EBITDA margin of 27% are strong indicators of operational efficiency, especially given the competitive Canadian market. While specific comparable company data is not provided in the filing, these margins suggest the company is performing well within the industry, particularly with its focus on higher-margin products.
• The 690% increase in international medical export sales for Canadian Cannabis is a significant outlier, indicating exceptional success in penetrating new global markets compared to typical industry growth rates for established cannabis producers.
• Leli Holland's rapid market penetration of 82.5% (products in 66 of 80 participating coffeeshops) in the nascent Dutch adult-use market is a strong early indicator of effective market entry and product acceptance, potentially setting a benchmark for other companies entering similar regulated markets.
• The refinancing of Canadian Cannabis Term Loans at a variable interest rate below 6.0%, a 250 basis point improvement, suggests the company's improved financial health and creditworthiness are being recognized by lenders, potentially better than some peers facing higher borrowing costs in the current interest rate environment.

Management Changes

Related Party Transactions

• The company entered into service and supply agreements with Vanguard Fresh Canada ULC for produce production in its Delta 1 and Delta 2 greenhouses, which will continue supplying produce to Vanguard for a multi-year term. This is a result of the privatization transaction where Village Farms retains a 37.9% equity ownership interest in Vanguard Food LP.

Stakeholder Impact

• **Shareholders:** Significant positive impact due to record profitability, strong cash flow, and strategic moves like the produce asset privatization and cannabis expansion, which are expected to drive long-term value creation and returns.
• **Employees:** Potential positive impact from growth and expansion, particularly in the cannabis segment, which may lead to job stability or creation. The produce segment's reclassification and new agreements with Vanguard Fresh Canada ULC clarify roles for employees in those operations.
• **Customers:** Continued supply of cannabis products in Canada and international markets, with new product categories (e.g., hash in Netherlands) and improved packaging (windowed flower products) enhancing customer experience. Produce customers will now be served by Vanguard Fresh Canada ULC for certain operations.
• **Suppliers:** Continued relationships with suppliers for cannabis cultivation and other operations, potentially expanding with increased capacity.
• **Creditors:** Improved financial health, strong cash position, and successful refinancing of term loans at a lower interest rate enhance the company's creditworthiness and ability to meet obligations.

Next Steps

• Continue ramping up operations in Leli Holland's Phase I facility in Drachten.
• Launch hash products in the Netherlands market during the fourth quarter of 2025.
• Continue construction of Leli Holland's Phase II facility in Groningen, aiming for operational status in Q1 2026.
• Proceed with the investment to expand cannabis cultivation capacity in the Delta 2 greenhouse for an incremental 40 metric tons of annualized production.
• Await review and decision on the Texas medicinal marijuana license application.
• If awarded the Texas license, work with listing authority to structure an acceptable ownership and comply with regulatory requirements to enter the U.S. THC market.
• Delta 2 greenhouse will cease supplying produce to Vanguard after the 2025 tomato crop.

Key Dates

Recommendation

The filing reveals exceptional financial performance, marked by record profitability, substantial increases in Adjusted EBITDA, and a strong positive shift in operating cash flow from continuing operations. The strategic divestiture of non-core produce assets, coupled with significant growth in the high-margin cannabis segments (Canadian and international exports, and the successful launch in the Netherlands), positions the company for sustained profitable growth. The balance sheet is robust with $65 million in cash, enabling self-funded expansion. The refinancing of debt at a lower interest rate further strengthens financial flexibility. While the U.S. cannabis market remains pending, the company's current trajectory and strategic focus on high-growth, high-margin opportunities make it a compelling 'strong buy' for investors seeking exposure to the evolving global cannabis industry.

Keywords

Cannabis, Marijuana, Hemp, CBD, Controlled Environment Agriculture, Greenhouse, Financial Results, SEC Filing, Earnings, Adjusted EBITDA, Produce, International Sales, Canada, Netherlands, USA, Cultivation, VFF